Mindstate Design Labs

Executive Summary

Mindstate Design Labs is a clinical-stage AI neuroengineering and psychedelic drug development company founded in 2021 to address the mental health crisis. The company leverages its proprietary AI platform, Osmanthus, to map the biological basis of emotion and cognition, enabling precision drug discovery. Unlike traditional psychedelic companies, Mindstate aims to design novel compounds that induce specific altered states of consciousness—such as empathy or awe—that are therapeutically valuable, moving beyond classical hallucinogens. The company has advanced its lead asset into Phase 3 clinical trials, targeting major depressive disorder. By combining AI-driven target identification with neuropsychiatric insights, Mindstate seeks to create a new class of medicines with improved efficacy and safety profiles. The company's progress to late-stage trials reflects its scientifically rigorous approach and growing credibility, though details on financing and valuation remain undisclosed. With a differentiated platform and a focus on treating root causes of mental illness, Mindstate Design Labs is positioned to be a leader in the next wave of neuropsychiatric therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Topline Data Readout for Lead Psychoplastogen Compound65% success
• Q3 2026FDA Pre-NDA Meeting or Breakthrough Therapy Designation for Lead Indication30% success
• Q2 2026Publication of Osmanthus AI Platform Validation or Partnering Deal50% success